MOBILE, Ala. (WKRG) — The University of South Alabama Mitchell Cancer Institute in Mobile is one of the few organizations splitting a $1,050,000 donation by the Breast Cancer Research Foundation of Alabama (BCRFA).
Funds being invested in the Mobile community by the BCRFA include three research projects at USA Mitchell:
- Dr. Natalie Gassman and Dr. Michelle Schuler
(2019 BCRFA Innovation Award Winners) – “Blockage of CHK1 and EGFR Signaling in
Triple Negative Breast Cancer to Enhance Anti-Tumor Efficacy” This project
focuses on how the lack of hormone and growth factor receptors in triple
negative breast cancer makes DNA damaging chemotherapies a first-line
treatment. Cardiotoxicity is a significant problem for these therapies. Dr.
Gassman and Dr. Scheler will test a novel combination of chemical inhibitors
that are only modestly effective on their own but have the potential in
combination to trigger death in triple negative cancer cells without cardiac
- Dr. Gabrielle Roque and Dr. Casey Daniels (receiving
their second year of support for a collaborative research project between
O’Neal Comprehensive Cancer Center at UAB and USA Mitchell) – “Quantifying
Breast Cancer Patient Preferences and their Association with Financial Toxicity
during Treatment Decision-Making” In this project Dr. Roque and Dr. Daniels
plan to quantify the trade-offs that breast cancer patients make during
treatment decisions, with a focus on financial toxicity. Their central
hypothesis is that increased understanding of patient preferences, particularly
those associated with financial toxicity, through the evaluation of trade-offs,
will optimize shared decision making (SDM). Quantification of breast cancer
patient preferences will create opportunities for patient participation in
decision-making, aid clinicians in understanding patient perspective during
treatment decision-making, and ultimately achieve patient-centered, higher
value healthcare for women living with breast cancer.
- Dr. Gary Piazza and Dr. Clint Grubbs (Collaboration between O’Neal Comprehensive Cancer Center at UAB and USA Mitchell) – “A Novel Wnt/β-catenin Inhibitor for Breast Cancer Therapy” This research is based on results from a two-year project funded in 2017 by the BCRFA. From this research project, they found a very promising compound named MCI-715 strongly inhibited tumorigenesis in a mouse model of breast cancer. Funds from the BCRFA will be used to evaluate the activity of MCI-715 in animal model trials for aggressive ER-breast cancer, and compare results against the current standard-of-care drug.
This donation announcement makes a total of almost $10 million donated y BCRFA since 1996. Other organizations receiving funds
To learn more about BCRFA, click here.
- 5 Things To Do This Weekend: February 21-23
- Cat defies odds and survives arrow to the head
- Migrants on one-way flights out of McAllen help break airport’s travel record
- Connecting the past and present through music
- Kentucky teen dies in apparent animal attack